Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
News|Articles|December 4, 2025
Dermatology Conferences and Meetings Calendar: December 2025
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- A list of dermatological meetings for December 2025 has been compiled from reader responses, highlighting anticipated events for professionals.
- Readers are invited to share their 2026 conference plans, fostering community engagement and understanding of professional interests.
Dermatology Times has compiled a list of dermatological meetings taking place during the month of December.
Advertisement
Dermatology Times has asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in 2025.
Using these responses, we have compiled a list of dermatological meetings taking place in December
Interested in sharing what conferences you are interested in or planning to attend in 2026? Email our team at
December
December 4-5, 2025: Riptide Dermatology
Palm Coast, Florida
December 5-6, 2025: Skin of Color Society Meeting the Challenge Summit
Washington, DC
December 5-7, 2025: 2025 Masters of Aesthetics Symposium East Coast
Miami, Florida
December 5-7, 2025: Mount Sinai Winter Symposium: Advances in Medical, Surgical, and Cosmetic Dermatology
New York, New York
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
2
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
3
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
4
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
5